Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$134.56
+1.3%
$145.49
$95.36
▼
$156.92
$331.46B0.1310.52 million shs5.78 million shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$10.00
-5.4%
$15.89
$9.98
▼
$29.23
$7.97B-1.494.82 million shs2.82 million shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-3.64%-9.69%-10.43%-12.92%+39.49%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
+0.67%-29.86%-34.31%-19.68%-36.17%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$134.56
+1.3%
$145.49
$95.36
▼
$156.92
$331.46B0.1310.52 million shs5.78 million shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$10.00
-5.4%
$15.89
$9.98
▼
$29.23
$7.97B-1.494.82 million shs2.82 million shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-3.64%-9.69%-10.43%-12.92%+39.49%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
+0.67%-29.86%-34.31%-19.68%-36.17%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.62
Moderate Buy$155.7417.33% Upside
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
2.56
Moderate Buy$28.10165.85% Upside

Current Analyst Ratings Breakdown

Latest SMMT and MRK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/18/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
DowngradeMarket Perform ➝ Underperform$11.90 ➝ $8.30
11/17/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
UpgradeStrong Sell ➝ Hold
11/16/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Lower Price TargetBuy$43.00 ➝ $42.00
11/16/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Lower Price TargetEqual Weight$20.00 ➝ $18.00
11/15/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Reiterated RatingBuy
11/3/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Initiated CoverageStrong-Buy
11/3/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
DowngradeBuy ➝ Hold$153.00
11/2/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Boost Price TargetHold$125.00 ➝ $140.00
11/2/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Boost Price TargetNeutral$145.00 ➝ $155.00
10/30/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Boost Price TargetOverweight$165.00 ➝ $175.00
10/30/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Lower Price TargetSector Perform$145.00 ➝ $140.00
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$65.01B5.03$11.01 per share12.06$18.23 per share7.28
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/A$0.71 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$18.25B$0.97136.8514.626.323.64%16.73%5.88%2/2/2027 (Estimated)
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$1.08B-$1.07N/AN/AN/AN/A-138.82%-117.11%N/A

Latest SMMT and MRK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/29/2026Q3 2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.09$2.49+$0.40$2.04$17.33 billion$18.09 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.402.56%+5.75%350.52%14 Years
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/AN/A

Latest SMMT and MRK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
11/17/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.882.46%12/15/202612/15/20261/8/2027
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
1.11
1.35
1.14
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/A
5.99
5.99

Institutional Ownership

CompanyInstitutional Ownership
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
4.61%

Insider Ownership

CompanyInsider Ownership
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.17%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
81.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.47 billion2.46 billionOptionable
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
265799.76 million145.56 millionOptionable

Recent News About These Companies

Summit Therapeutics (NASDAQ:SMMT) Shares Down 6.8% on Analyst Downgrade
Summit Therapeutics (SMMT) Gets a Hold from Barclays
Summit Therapeutics (SMMT) Is Losing Wall Street’s Confidence
Summit Therapeutics (SMMT) Hits 52-Week Low After FDA Setback
2 Cancer-Drug Developers Seeing Unusual Options Volume
Summit and Akeso shares plunge after FDA rejects ivonescimab

New MarketBeat Followers Over Time

Media Sentiment Over Time

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$134.56 +1.75 (+1.32%)
As of 12:47 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Summit Therapeutics stock logo

Summit Therapeutics NASDAQ:SMMT

$10.00 -0.57 (-5.43%)
As of 12:47 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.